Redeye comments on the third quarter report of BioInvent. All projects are progressing. Importantly, BI-1808 is the second program, after BI-1206, to advance into phase II. The subcutaneous version of BI-1206 is being studied with results expected by H1 2024 in lymphoma.
LÄS MER